Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more
Market Cap & Net Worth: Genovate Biotechnology Co Ltd (4130)
Genovate Biotechnology Co Ltd (TWO:4130) has a market capitalization of $111.39 Million (NT$3.69 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #19315 globally and #950 in its home market, demonstrating a -7.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genovate Biotechnology Co Ltd's stock price NT$32.40 by its total outstanding shares 113750529 (113.75 Million).
Genovate Biotechnology Co Ltd Market Cap History: 2015 to 2026
Genovate Biotechnology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $184.20 Million to $111.39 Million (-0.14% CAGR).
Genovate Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genovate Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.19x
Genovate Biotechnology Co Ltd's market cap is 0.19 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
8.15x
Genovate Biotechnology Co Ltd's market cap is 8.15 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $110.90 Million | $411.20 Million | $39.21 Million | 0.27x | 2.83x |
| 2017 | $94.83 Million | $408.27 Million | $148.97 Million | 0.23x | 0.64x |
| 2018 | $80.97 Million | $455.80 Million | $57.85 Million | 0.18x | 1.40x |
| 2019 | $75.93 Million | $465.76 Million | $34.05 Million | 0.16x | 2.23x |
| 2020 | $93.37 Million | $472.72 Million | $38.73 Million | 0.20x | 2.41x |
| 2021 | $80.64 Million | $434.25 Million | $372.00K | 0.19x | 216.77x |
| 2022 | $107.15 Million | $438.76 Million | -$12.32 Million | 0.24x | N/A |
| 2023 | $88.20 Million | $528.51 Million | $29.33 Million | 0.17x | 3.01x |
| 2024 | $71.51 Million | $510.86 Million | $25.70 Million | 0.14x | 2.78x |
| 2025 | $95.23 Million | $492.41 Million | $11.68 Million | 0.19x | 8.15x |
Competitor Companies of 4130 by Market Capitalization
Companies near Genovate Biotechnology Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Genovate Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Genovate Biotechnology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Genovate Biotechnology Co Ltd's market cap moved from $184.20 Million to $ 111.39 Million, with a yearly change of -0.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$111.39 Million | +16.97% |
| 2025 | NT$95.23 Million | +33.17% |
| 2024 | NT$71.51 Million | -18.92% |
| 2023 | NT$88.20 Million | -17.69% |
| 2022 | NT$107.15 Million | +32.88% |
| 2021 | NT$80.64 Million | -13.63% |
| 2020 | NT$93.37 Million | +22.96% |
| 2019 | NT$75.93 Million | -6.22% |
| 2018 | NT$80.97 Million | -14.62% |
| 2017 | NT$94.83 Million | -14.49% |
| 2016 | NT$110.90 Million | -39.80% |
| 2015 | NT$184.20 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Genovate Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $111.39 Million USD |
| MoneyControl | $111.39 Million USD |
| MarketWatch | $111.39 Million USD |
| marketcap.company | $111.39 Million USD |
| Reuters | $111.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.